Enanta Pharmaceuticals Inc Stock Price, News & Analysis

Enanta Pharmaceuticals (NASDAQ: ENTA) has filed a patent infringement lawsuit against Pfizer in the Unified Patent Court (UPC) of the European Union. The lawsuit concerns European Patent No. EP 4 051 265, which relates to coronavirus protease inhibitors used in Pfizer's COVID-19 antiviral medication, Paxlovid™.

The legal action targets Pfizer's activities across 18 EU countries participating in the UPC. The patent in question is based on Enanta's July 2020 application and is the European counterpart to U.S. Patent No. 11,358,953, which is already involved in ongoing U.S. litigation between the companies. Under UPC procedures, a hearing is expected within a 12-month timeframe, with a decision following weeks after.

Enanta Pharmaceuticals (NASDAQ:ENTA) reported its fiscal Q3 2025 financial results, with total revenue of $18.3 million from royalties on AbbVie's HCV regimen MAVYRET®/MAVIRET®. The company posted a net loss of $18.3 million ($0.85 per share), improving from a $22.7 million loss in Q3 2024.

Key pipeline developments include: completion of enrollment in the RSVHR Phase 2 trial of zelicapavir for RSV treatment with topline data expected in September, ongoing IND-enabling studies for EPS-1421 (KIT inhibitor) for urticaria treatment, and progress toward selecting a STAT6 development candidate in 2H 2025. The company maintains a strong financial position with $204.1 million in cash and marketable securities, projected to fund operations into fiscal 2028.

XtalPi (2228.HK) and DoveTree Medicines have announced a groundbreaking $6 billion strategic collaboration in AI-driven drug discovery. The partnership combines XtalPi's AI and robotics platform with DoveTree's biological expertise to develop novel therapeutics across multiple disease areas.

Under the agreement, DoveTree receives exclusive global rights and will pay XtalPi an upfront payment of $51 million, with $49 million in near-term payments and up to $5.89 billion in milestone payments and tiered royalties. The collaboration will focus on developing first-in-class candidates in oncology, immunology, inflammation, neurology, and metabolic diseases.

DoveTree, founded by renowned drug developer Dr. Gregory Verdine, brings expertise in "drugging the undruggable" targets, while XtalPi contributes its intelligent de novo drug discovery platform spanning multiple modalities including small molecules, biologics, ADCs, and molecular glues.

Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotech company focused on developing small molecule drugs for viral infections and immunological diseases, will participate in a virtual fireside chat at the H.C. Wainwright & Co. "HCW@Home" series. The event is scheduled for Tuesday, August 12, 2025 at 1:00 p.m. ET.

Investors can access the live webcast through Enanta's website in the "Events and Presentations" section or via direct registration. A replay will be available after the presentation and archived for at least 30 days.

Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotech company focused on developing small molecule drugs for viral infections and immunological diseases, will participate in Baird's Biotech Discovery Series. The company's management will engage in a virtual fireside chat on July 22 at 1:30 p.m. ET.

Investors can access the live webcast through the "Events and Presentations" section on Enanta's website. A replay will be available and archived for at least 30 days after the event.

The FDA has approved an expanded indication for MAVYRET (glecaprevir/pibrentasvir), making it the first and only 8-week treatment approved for both acute and chronic Hepatitis C Virus (HCV) infection. Developed through a partnership between Enanta Pharmaceuticals (NASDAQ:ENTA) and AbbVie, MAVYRET demonstrated a 96% cure rate in clinical trials. The treatment is approved for adults and children aged 3 and older, with or without compensated cirrhosis. The FDA granted Breakthrough Therapy Designation based on Phase 3 trial results showing high efficacy with mild to moderate adverse events. Over one million chronic HCV patients have been treated with MAVYRET, and this expansion allows immediate treatment upon diagnosis, potentially preventing progression to chronic disease and supporting global HCV elimination goals by 2030.

Enanta Pharmaceuticals (NASDAQ: ENTA), a clinical-stage biotech company focused on developing small molecule drugs for viral infections and immunological diseases, has announced that its President and CEO, Jay R. Luly, Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference. The presentation is scheduled for June 5, 2025, at 8:10 a.m. ET in New York. Investors can access the live webcast through Enanta's website, and a replay will be available for at least 30 days after the event.

Enanta Pharmaceuticals (NASDAQ:ENTA) reported its fiscal Q2 2025 financial results with key developments in its virology and immunology pipeline. The company achieved target enrollment of 180 patients in RSVHR Phase 2 study of zelicapavir for RSV treatment, with topline data expected in late Q3 2025. Financial highlights include revenue of $14.9 million from MAVYRET royalties (down from $17.1M in Q2 2024), and a net loss of $22.6 million ($1.06 per share). Cash position stands at $193.4 million, further strengthened by a $33.8 million federal tax refund received in April 2025. The company's pipeline progress includes STAT6 program advancement with plans for development candidate selection in 2H 2025, and ongoing IND enabling studies for KIT inhibitor EPS-1421. Enanta expects current financial resources to fund operations into fiscal 2028.

Enanta Pharmaceuticals (NASDAQ:ENTA) has announced that data from their Phase 2a human challenge study of EDP-323, a first-in-class oral RSV treatment, will be presented at ESCMID Global 2025 in Vienna, Austria. The presentation will showcase results from the study, which were initially announced in September 2024, including new data on respiratory mucus production.

EDP-323 is a non-nucleoside small-molecule inhibitor targeting the RSV polymerase (L-protein). The ePoster presentation, titled 'EDP-323, a First-in-Class, Oral, RSV L-Protein Inhibitor Reduces Disease Severity (Respiratory Mucus Production) and Accelerates Viral Clearance in a Human Viral Challenge Study,' will be presented by Dr. John P. DeVincenzo on April 13, 2025, at 8:30 a.m. CEST.